Search Within

Stephen D Nimer

Formats
  1. Journal Article (181)
  2. Meeting Abstract (162)
  3. Book Section (2)
  4. Conference Paper (2)
Groups
  1. Department of Medicine (347)
  2. Hematologic Malignancies, Division of (347)
  3. Center for Hematologic Malignancies (121)
  4. Adult Leukemia (57)
  5. GSK Faculty (56)
  6. Survivorship Research (50)

More Groups

People
  1. Craig Moskowitz (46)
  2. Andrew Zelenetz (40)
  3. Tarun Kewalramani (40)
  4. Raymond Comenzo (36)
  5. Hani Hassoun (31)
  6. Virginia Klimek (30)

More People

Years
  1. 2017 (1)
  2. 2014 (3)
  3. 2013 (8)
  4. 2012 (19)
  5. 2011 (24)
  6. 2010 (17)

More Years

Publications
  1. Blood (175)
  2. Cancer Research (12)
  3. Oncogene (9)
  4. British Journal of Haematology (8)
  5. Leukemia Research (8)
  6. Bone Marrow Transplantation (7)

More Publications

Publishers
  1. American Society of Hematology (176)
  2. Nature Publishing Group (29)
  3. American Association for Cancer Research (19)
  4. Elsevier Inc. (12)
  5. Cell Press (11)
  6. John Wiley & Sons (9)

More Publishers

Results (347)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term clinical benefit of lenalidomide (Revlimid) treatment in patients with Myelodysplastic syndrome and chromosome deletion 5q
    Meeting Abstract

    List, A. F.; Dewald, G. W.; Bennett, J. M.; Giagounidis, A.; Raza, A.; Feldman, E. J.; Powell, B. L.; Greenberg, P. L.; Nimer, S. D.; Zeldis, J. B.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • The role of cyclin C on hematopoietic cells
    Meeting Abstract

    Lie, Y.; Sashida, G.; Nimer, S.; Miyata, Y.
    Blood (2006)

    Fulltext@MSK | Save
  • Identification of key cellular regulators that interact with Id1 to control hematopoietic stem cell behavior
    Meeting Abstract

    Jankovic, V.; Ciarrocchi, A.; Deblasio, T.; Benezra, R.; Nimer, S. D.
    Blood (2006)

    Fulltext@MSK | Save
  • The deletion of NHR1 region of the AML1-ETO protein significantly decreases its ability to promote proliferation and self-renewal of early hematopoietic cells in culture
    Meeting Abstract

    Gural, A.; Jankovic, V.; Zhang, J.; Roeder, R. G.; Nimer, S. D.
    Blood (2006)

    Fulltext@MSK | Save
  • Mobilization of blood stem cells with G-CSF in systemic light-chain amyloidosis: Dominant organ involvement significantly affects stem cell collection
    Meeting Abstract

    Comenzo, R.; Hassoun, H.; Reich, L.; Collins, N.; Nuta, A.; Chen, X. S.; Zhou, P.; Clark, B.; Teruya-Feldstein, J.; Fleisher, M.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Risk-adapted melphalan (MEL) with stem cell transplant (SCT) and adjuvant dexamethasone (D)+/- thalidomide (T) for AL patients achieves low treatment-related mortality (TRM) and high hematologic response rates
    Meeting Abstract

    Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Clark, B.; Stubblefield, M.; Fleisher, M.; Nimer, S. D.; more...
    Amyloid (2006)

    Fulltext@MSK | Save
  • Induction of remission prior to transplantation improves the disease-free survival (DFS) of patients with advanced myelodysplastic syndromes (MDS) treated with myeloablative T - Cell depleted (TCD) stem cell transplants (SCT) from histocompatible unrelated donors
    Meeting Abstract

    Castro-Malaspina, H. R.; Jakubowski, A. A.; Papadopoulos, E. B.; Boulad, F.; Young, J. W.; Kernan, N. A.; Perales, M. A.; Small, T. N.; Chiu, M.; Heller, G.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • CD32B on clonal plasma cells in systemic light-chain amyloidosis (AL) and multiple myeloma (MM): A target for immunotherapy in both disorders and a prognostic marker in MM
    Meeting Abstract

    Boruchov, A.; Zhou, P.; Olshen, A.; Rankin, C.; Bonvini, E.; Koenig, S.; Fleisher, M.; Rose, R.; McKenzie, S.; Maslak, P.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
    Journal Article

    Heidel, F.; Solem, F. K.; Breitenbuecher, F.; Lipka, D. B.; Kasper, S.; Thiede, M. H.; Brandts, C.; Serve, H.; Roesel, J.; Giles, F.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics
    Journal Article

    DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; more...
    Blood (2006)

    Fulltext@MSK | Save